Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026

HomeCompaniesSectorsCalendarLast night
Screens
WarningsPrice and conditionThen and nowSize bandsCeased filers
Tools
Time machinePoint in timeData exportsRun logForecast logEDGAR company search
Method
MethodCoverageAbout
Kairos Pharma, Ltd.KAPA · healthcare
GradeNonecomputable_factors_below_threshold: 2 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $6.5M[1]
Warningslate filer, thin datanot computable: dilution, degenerate inputs, distress, fortress balance sheet
Inputs computable2 of 14
Graded fromfilings received through Mar 31, 2026192 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.932026-10-08; market equity $22.0M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$1$2NovDecJanFebMarAprMayJunJulAugSepOct$0.96
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2025nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 31, 2026; the document on sec.gov.

are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies mission is to advance our portfolio of innovative therapeutics to target key mechanisms of therapeutic resistance and immune suppression and transform the way cancer is treated.

Warnings [top]

Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 2 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 13.5
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(32.6%)[1-4](6.6%)13.58112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 2.0
Twelve-month failure probabilitynot computable0.07%
liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-primenot computable(0.31)
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio27.07x[5-6]2.96x2.08392025-12-31
Growth and financing
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 0
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 0
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three yearsnot computable2.1%
four annual observations are required; found 2
Net share issuance, one yearnot computable2.5%
prior share count is 246 days earlier

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month43.6%8.0%72hotter than 72 of 100 peers
Distance from 52-week high(59.8%)(31.4%)18closer to its high than 18 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yieldnot computable(1.0%)required accounting or market input is missing
Book value to price0.180.2838pricier than 62 of 100 peers
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five yearsnot computable20.3%a share count from five years earlier is required
Relative strength against the sector, log excess return0.15(0.14)72ahead of 72 of 100 peers

Inputs: market equity $22.7M; EBIT -$5.6M; book equity $4.2M; cash $2.6M[7].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(94.4%)✗ fail[2,4]
Operating cash flow above zero-$3.4M✗ fail[3]
Return on assets improvedn/a[2,4,8]
Operating cash flow exceeds net income$2.0M✓ pass[2-3]
Long-term leverage felln/a[1,4]
Current ratio improved2,286.8 pts✓ pass[5-6,9-10]
No new shares issuedn/a[11-12]
Gross margin improvedn/a
Asset turnover improvedn/a[4]
Cash, filings, liquidity
Cash and equivalents$2.6M[13]
Operating cash flow, four quarters-$4.0M[3,13-17]
Months of runway7.9
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing58
10-Q received Aug 12, 2026
Median daily dollar volume$135,994
63 sessions
Days since newest grade input192

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$6.5M2025-12-312026-03-3110-Kfiling · viewer · series
2net incomeus-gaap:NetIncomeLoss-$5.4M2025-12-312026-03-3110-Kfiling · viewer · series
3operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.4M2025-12-312026-03-3110-Kfiling · viewer · series
4assetsus-gaap:Assets$5.8M2024-12-312026-03-3110-Kfiling · viewer · series
5current assetsus-gaap:AssetsCurrent$5.4M2025-12-312026-03-3110-Kfiling · viewer · series
6current liabilitiesus-gaap:LiabilitiesCurrent$199,0002025-12-312026-03-3110-Kfiling · viewer · series
7shares outstandingdei:EntityCommonStockSharesOutstanding23,697,6832026-08-122026-08-1210-Qfiling · viewer · series
8net incomeus-gaap:NetIncomeLoss-$2.6M2024-12-312026-03-3110-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$4.2M2024-12-312026-03-3110-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$992,0002024-12-312026-03-3110-Kfiling · viewer · series
11shares outstandingdei:EntityCommonStockSharesOutstanding21,411,1982026-03-312026-03-3110-Kfiling · viewer · series
12shares outstandingdei:EntityCommonStockSharesOutstanding20,457,4802025-07-282025-07-2810-K/Afiling · viewer · series
13cashus-gaap:CashAndCashEquivalentsAtCarryingValue$2.6M2026-06-302026-08-1210-Qfiling · viewer · series
14operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.0M2026-06-302026-08-1210-Qfiling · viewer · series
15operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$1.0M2026-03-312026-05-1310-Qfiling · viewer · series
16operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.4M2025-09-302025-11-1410-Qfiling · viewer · series
17operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$1.5M2025-06-302026-08-1210-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.

Informational and educational only. Not investment advice. SEC and market data may contain errors.

If you have any comments about this page, the methodology and every line of code that produced it are in the public repository. However, due to the limited number of personnel, we are unable to provide a direct response.

Pages
Home · Companies · Sectors · Calendar · Last night
Screens
Warnings · Price and condition · Then and now · Size bands · Ceased filers
Tools
Time machine · Point in time · Data exports · Run log · Forecast log · EDGAR company search
Method
Method · Coverage · About
Source
GitHub · ezrakruger.cc
Photographs from Wikimedia Commons

bull: Raphael Schön from Vienna, Austria, CC BY 2.0; bear: U. S. Fish and Wildlife Service - Northeast Region, Public domain; elk: Oregon Department of Fish & Wildlife, Public domain; tortoise: NPS, Public domain; sloth: Charles J. Sharp, CC BY-SA 3.0; fox: Cp9asngf, CC BY-SA 4.0; sector-business_equipment: Sangitiana Fararano, CC BY-SA 2.0; sector-healthcare: User:Squidonius, myself, and User:Beliason (assumed)., CC BY-SA 4.0; sector-manufacturing: unknown, CC BY-SA 2.0; sector-shops: Wilfredor, CC BY-SA 4.0; sector-consumer_nondurables: Nielsoncaetanosalmeron, CC BY 4.0; sector-utilities: Lijovklm, CC BY-SA 4.0; sector-consumer_durables: Stilfehler, CC BY-SA 4.0; sector-chemicals: PEO ACWA, CC BY 2.0; sector-energy: Arne Hückelheim, CC BY-SA 3.0; sector-telecom: Wikideas1, CC0; sector-other: Downtowngal, CC BY-SA 4.0.

Updated Oct 9, 2026